Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 47 Publications

11 Customer Reviews

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

    HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

  • U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3WNE0yOCEQvF2= NWLHe205OC12IHS= M2PvNYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mm\TNlY4ODJ5OES=
HepG2 MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TXUlAuOTBizszN NE[3SFcxNTRiZB?= MWHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYO4OGVYOjZ5MEK3PFQ>
HT29 M4SyVGZ2dmO2aX;uJGF{e2G7 NW[1VGhuPTEEoH7N MmrzNlQuPzJiaB?= NFHnellqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDR6wrDoxsA> M{TSbFI3PzB{N{i0
HepG2 M{PTc2Z2dmO2aX;uJGF{e2G7 NVTmVFQ1PTEEoH7N NELHRXkzPC15MjDo MV;pcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G|cHHz[UA{KGGodHXyJFI1yqCqwrC= NIjEbXkzPjdyMke4OC=>
HCC827 NEDDdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jVO|UwPy53L{GwJI5O NXXiOYhwPzMEoHi= M3vDSmROW09? NUHpZ5ht\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= Mly3NlY3PzV2OES=
A549  MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOxNE8yPS9{MDDuUS=> MlrCO|LDqGh? M{LIfWROW09? Mkm4[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? MWSyOlY4PTR6NB?=
NCI-H460  NF;wWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKxNE8zOC9|MDDuUS=> M3KwOVczyqCq NYHFSYM2TE2VTx?= NIrrTIhmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= M2jJflI3Pjd3NEi0
J89GFP M2TERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHUR5I{TE2VT9Mg MWjFR|UxRTR7Lki1JOKyKDF{Lk[1JI5O MUOyOlU3OzV4OB?=
THP89GFP MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHlSG1UV8Li NVTneY4yTUN3ME2xPU4{PCEEsTC2MlQ{KG6P NWOxUId{OjZ3NkO1Olg>
SK-NEP-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPrTXlwOC5yMfMAl|ExNjBizszN M1jwb|I1KGh? NY\1fIZkTE2VT9Mg MkjiTWM2OD15Nj6zOEBvVQ>? M2P3PFI3OTd4MkG5
G401 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmwMlAy6oDVMUCuNEDPxE1? NX6wN4pqOjRiaB?= MnH5SG1UV8Li MYPJR|UxRTF2Mz6wNkBvVQ>? MWWyOlE4PjJzOR?=
SK-NEP-1 NWDNVWRlS2WubDDWbYFjcWyrdImgRZN{[Xl? Mn7xOVAhdk1? M{fZ[|HjiJN2IHS= M1q1O2ROW00EoB?= MV3y[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> M2LHcVI3OTd4MkG5
G401 M2nqWmNmdGxiVnnhZoltcXS7IFHzd4F6 M3X3PVUxKG6P NGq2fG8y6oDVNDDk NW\wbVVuTE2VT9Mg MkXzdoVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz M3rZdlI3OTd4MkG5
SK-NEP-1 NHvFVGNCeG:ydH;zbZMhSXO|YYm= MX61NE8yODBibl2= NGfGSnIzPCCq NUTSVoZpTE2VT9Mg MoPlbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MV:yOlE4PjJzOR?=
G401 M2n2bWFxd3C2b4Ppd{BCe3OjeR?= MnLROVAwOTByIH7N NGjaOGwzPCCq NVroc3Y{TE2VT9Mg M3S2WYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M362NFI3OTd4MkG5
SK-NEP-1 NEPMS|lHfW6ldHnvckBCe3OjeR?= MYG1NE8yODBibl2= NVnnN282OjRiaB?= NEnuNVJFVVORwrC= MWXzbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v M3Ow[FI3OTd4MkG5
G401 Ml7wSpVv[3Srb36gRZN{[Xl? MWG1NE8yODBibl2= NHf6NJAzPCCq MmfmSG1UV8Li NYfJelhje2ixd4OgeIhmKGmwZIXjeIlwdiCxZjDEUmEh\nKjZ33lcpRifGmxbh?= NGnERVYzPjF5NkKxPS=>
SK-NEP-1 NWnqTm9vTnWwY4Tpc44hSXO|YYm= Mkj0OVAwOTByIH7N M{\WdFI1KGh? MX\EUXNQyqB? NV7ybFE3cW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? MVqyOlE4PjJzOR?=
G401 M1\DdWZ2dmO2aX;uJGF{e2G7 NIL4cVI2OC9zMECgcm0> M3vTfVI1KGh? NGfGUoFFVVORwrC= M3iydolv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh MVyyOlE4PjJzOR?=
RPMI 8226 NEDNTVdE\WyuIGP1dpZqfmGuIFHzd4F6 Mnq4Nk81NzZibl2= NVPxT2VwPDkkgJno M4f5UIlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? NIi5fnkzPjByMEK5Ni=>
OPM2 NWLifJA3S2WubDDTeZJ3cX[jbDDBd5NigQ>? M1Xx[VIwPC94IH7N MWO0PQKBkWh? MVfpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp MVeyOlAxODJ7Mh?=
U266 NYXFc2J4S2WubDDTeZJ3cX[jbDDBd5NigQ>? NGSydpgzNzRxNjDuUS=> MYG0PQKBkWh? M1jhdIlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? MnOzNlYxODB{OUK=
H929 M4rW[GNmdGxiU4Xyeol3[WxiQYPzZZk> NIH2VlkzNzRxNjDuUS=> NG\hWII1QOLCiXi= NUPNeodHcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= M4LqVFI3ODByMkmy
RPMI 8226  NY[wWWVPSXCxcITvd4l{KEG|c3H5 MVy05qCKdk1? NHv1TIQzPC92ODDo Mmf1bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NWHCRmF2OjZyMECyPVI>
HCC827 NIPXSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLXNVAhdk1? NWHifXJ6PDhiaB?= M3jKPWROW09? NWHrSo9Q\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= MmjTNlU6PDR4MUe=
NCI-H23 NF3GfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[5NVAhdk1? NWDySVl2PDhiaB?= NVjhNXF[TE2VTx?= Mnm1[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB? M1nvNFI2QTR2NkG3
AML3 MlnjSpVv[3Srb36gRZN{[Xl? MoC5NE0yKM7:TR?= MXOyOOKhcA>? NXjWWppbcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYOyOVYyOjl2MR?=
ML-1 M1PDXGZ2dmO2aX;uJGF{e2G7 MnjPNE0yKM7:TR?= M3y3cVI1yqCq Mn;MbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnmzNlU3OTJ7NEG=
RPMI-8226vr10  MYLGeY5kfGmxbjDBd5NigQ>? NID1WXAxNTFizszN NFPidWUzPMLiaB?= MlXabY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2HlelI2PjF{OUSx
ML-1 M4LkZ2Z2dmO2aX;uJGF{e2G7 NIriXpIyKM7:TR?= NUXVPXJZOjUEoHi= MX7pcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFQu\m:uZB?= NUDWXpBjOjV4MUK5OFE>
RPMI-8226vr10  NXvKXWdDTnWwY4Tpc44hSXO|YYm= NVH3OZIyOSEQvF2= NHPWUJQzPMLiaB?= MnTxbY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUAzNjVvZn;s[C=> NGn4eJYzPTZzMkm0NS=>
SK-N-BE (2) M2OwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWyOQKBkWh? MVXJR|UxRTFyND6w5qCKyrIkgJm3Mlghdk1? Ml;nNlU{ODh7MU[=
SK-N-BE (2), PAN  MK MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSyOQKBkWh? NXm4fpF[UUN3ME2xNFQvOOLCidMx5qCKPy56IH7N MoHnNlU{ODh7MU[=
SK-N-BE (2), MK  PAN MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYWyOQKBkWh? MmntTWM2OD1|OEKuNQKBkcLz4pEJOFMvOiCwTR?= NHrjXJkzPTNyOEmxOi=>
SK-N-AS MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXOxVmpyOjUkgJno Ml3sTWM2OD1|Nz6x5qCKyrIkgJmyMlQhdk1? M3;pNFI2OzB6OUG2
SK-N-DZ MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;MO|I16oDLaB?= Mn;XTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1? M2\ZT|I2OzB6OUG2
Caki-1 NWqySHRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPyNVAwOjVxNUCgcm0> MVK0PEBp MlHCbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ NFPrfW8zPTJ5OUG5NS=>
ACHN MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrQfo0yOC9{NT:1NEBvVQ>? NG\WNJc1QCCq NIjO[IRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= M3LwVVI2Ojd7MUmx
769-P MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWexNE8zPS93MDDuUS=> MUG0PEBp NEfod|hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= NWLiXHE2OjV{N{mxPVE>
786-O  MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHWNVAwOjVxNUCgcm0> NWjIOZl2PDhiaB?= NGq3XYFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MV2yOVI4QTF7MR?=
Caki-1 MW\BdI9xfG:|aYOgRZN{[Xl? M2jMT|UxKG6P M37WeFQ5KGh? NGPYU2FqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= M2DteVI2Ojd7MUmx
ACHN NUDtfppZSXCxcITvd4l{KEG|c3H5 MUi1NEBvVQ>? MWS0PEBp M3[1T4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ MlzNNlUzPzlzOUG=
769-P MX3BdI9xfG:|aYOgRZN{[Xl? Ml\LOVAhdk1? MmHqOFghcA>? MonKbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? Mo\xNlUzPzlzOUG=
786-O  MnLIRZBweHSxc3nzJGF{e2G7 MVi1NEBvVQ>? M4DsRVQ5KGh? NH3tUYhqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NFuwe|MzPTJ5OUG5NS=>
Caki-1 M4PCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTrU5ozPS93MDDuUS=> MV20PEBp NIP1WlJFVVOR NEOxbYtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni NUHNUlNHOjVzN{[zOVQ>
ACHN MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCyOU82OCCwTR?= NYnOdZA{PDhiaB?= M4\RRmROW09? NGe3[oJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni NF;UXogzPTF5NkO1OC=>
769-P NVy4ZWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3LPYgzPS93MDDuUS=> NWnzRZU2PDhiaB?= NIrFZVdFVVOR NEjC[ppqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni M{jtdlI2OTd4M{W0
Caki-1 NWHFN|A{S2:ub375JGZwem2jdHnvckBCe3OjeR?= NXvOTnB1PTBibl2= NYS0foxjPy1zNDDk MUHEUXNQ MVXzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> MnG4NlUyPzZ|NUS=
ACHN MXHDc4xwdnliRn;ycYF1cW:wIFHzd4F6 NWnOeI1FPTBibl2= NI\qSlg4NTF2IHS= M2rtcGROW09? NGniPJJ{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? NYHiZnQ1OjVzN{[zOVQ>
769-P M33rTGNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? NFjwS2Y2OCCwTR?= M1fMWVcuOTRiZB?= NECwNllFVVOR MYLzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> NVPVXFNDOjVzN{[zOVQ>
Caki-1 M{T4OGFxd3C2b4Ppd{BCe3OjeR?= MXe1NEBvVQ>? NFS0eYg1QCCq NF71UIFFVVOR MWTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3jQOFI2OTd4M{W0
ACHN M4Czc2Fxd3C2b4Ppd{BCe3OjeR?= MoL5OVAhdk1? NYDxV3VHPDhiaB?= MVHEUXNQ MmK5bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYj3UHpJOjVzN{[zOVQ>
769-P M1vQU2Fxd3C2b4Ppd{BCe3OjeR?= NIC4dlg2OCCwTR?= M2HRNlQ5KGh? MnnwSG1UVw>? MlfnbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MWGyOVE4PjN3NB?=
MDA-MB-231 Mn;PUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 NYOwO4hNOTEEoH7N M3TJ[|PDqGR? MWHEUXNQ NUTPTW1K[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg NGjlR5EzPDhzMES5Oy=>
BT-549 MYHNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> MV:xNOKhdk1? M2rRV|PDqGR? M{T6[WROW09? NW\ZUZRX[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg MYWyOFgyODR7Nx?=
MCF-7  M1XxSm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? NUK2UVJGOTEEoH7N NYDPR5pPO8LiZB?= NFLUXVlFVVOR M{DEd4FtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= NFXvbVUzPDhzMES5Oy=>
MCF-7 MmS0SpVv[3Srb36gRZN{[Xl? MYK1MVUxKG6P NIrVeGMzPCCq MX;EUXNQ M1XrU5Jm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA> M2my[FI1OzZ4NEC3
CTS MmO4RZBweHSxc3nzJGF{e2G7 M1jYN|DjiJN2MDDuUeKh MUG0PEBp NVjWW5BncW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFXjO4czPDJ2NESyPS=>
OCI-AML3  NHTrcZhCeG:ydH;zbZMhSXO|YYm= M3f0dlDjiJN2MDDuUeKh NGHEUoU1QCCq MYrpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFzp[mgzPDJ2NESyPS=>
U937 MoPlRZBweHSxc3nzJGF{e2G7 MnjvNQKBmzRyIH7NxsA> MXy0PEBp M4jIOYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFzsU4UzPDJ2NESyPS=>
PC3 NHv6To9CeG:ydH;zbZMhSXO|YYm= MVywMVExOCCwTR?= NH\BNIozPC92ODDo NYL6bXhocW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MkPzNlQyPjN{M{C=
PC3-AR NXT2NmExSXCxcITvd4l{KEG|c3H5 M1jYXFAuOTByIH7N MWiyOE81QCCq NUfxcot[cW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWDpdlFROjRzNkOyN|A>
PC3 M4fXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELKelgxNTFyMDDuUS=> MoXWNlQwPDhiaB?= NHXmTGlqdmS3Y3XzJIFk[3WvdXzheIlwdiCxZjDzeYJIOSCyb4D1cIF1cW:w MWKyOFE3OzJ|MB?=
PC3-AR MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnud4IxOC1zMECgcm0> NUjRXGtmOjRxNEigbC=> MYTpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJJRp\SCJMl2gdIhie2V? MmL3NlQyPjN{M{C=
PC3 NIHhe41HfW6ldHnvckBCe3OjeR?= M4H1[VAuOTByIH7N Moe2NlQhcA>? MUTzeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= MVWyOFE3OzJ|MB?=
PC3-AR NEXmZm5HfW6ldHnvckBCe3OjeR?= M4rrUlAuOTByIH7N NYDhNmNXOjRiaB?= MWDzeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= M{HaUVI1OTZ|MkOw
OS-RC-2 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHrVNnoxNTFyMECgcm0> Mn:5NlQwPDhxN{KgbC=> NHXVSHlFVVOR MnvP[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXyyOFE1PDd|Nx?=
OS-RC-2 NU[3XFZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW1OVAhdk1? MlXZOFghcA>? NVjadI9vTE2VTx?= NIC2e4tqdmS3Y3XzJGczN01iYYLy[ZN1 NEXLU2EzPDF2NEezOy=>
OS-RC-2 MYHBdI9xfG:|aYOgRZN{[Xl? MVm1NEBvVQ>? NXLZb3liPDhiaB?= NIDYW4JFVVOR M3fMNolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NVjB[mRQOjRzNES3N|c>
SK-N-AS M33QNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fXTFDjiJN6MDDuUS=> M4DuPFQ5KGh? NWTxeFU4UUN3ME2yO{41KG6P MljlNlQxQTh5OUm=
SK-N-DZ MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnNfZFSOOLCk{iwJI5O M1e1cVQ5KGh? MX7JR|UxRTJzLkmgcm0> NV;TWVV7OjRyOUi3PVk>
SK-N-SH MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[w5qCUQDBibl2= MWi0PEBp MlSyTWM2OD15Mj6zJI5O MkfGNlQxQTh5OUm=
SK-N-BE MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3iV4Y5OOLCk{iwJI5O M2DjW|Q5KGh? MU\JR|UxRTd3LkSgcm0> NXvScml2OjRyOUi3PVk>
SK-N-AS NYrqfJVoSXCxcITvd4l{KEG|c3H5 MmLmNQKBmzhyIH7N MoXUOFghcA>? MlzndI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u NGnVfowzPDB7OEe5PS=>
SK-N-DZ NYTTOFRSSXCxcITvd4l{KEG|c3H5 M4K2UlDjiJN6MDDuUS=> M3:2WlQ5KGh? NVK5SG5IeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v NVzi[5oxOjRyOUi3PVk>
SK-N-SH MlfhRZBweHSxc3nzJGF{e2G7 NUH3PIxoOOLCk{SwJI5O MXq0PEBp MVHwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= NHrGOGMzPDB7OEe5PS=>
SK-N-BE NXvjW|VJSXCxcITvd4l{KEG|c3H5 NUDhe5hpOOLCk{SwJI5O NE\uTXk1QCCq Mle2dI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u Mm\FNlQxQTh5OUm=
SK-N-AS Ml7XSpVv[3Srb36gRZN{[Xl? NV;SNFVMOOLCk{iwJI5O MUK0PEBp MlLtbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> MoOyNlQxQTh5OUm=
SK-N-DZ NX7YOYZ2TnWwY4Tpc44hSXO|YYm= NIHNZ5Ax6oDVOECgcm0> MlH4OFghcA>? M4fxXYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> MYGyOFA6QDd7OR?=
SK-N-SH MknnSpVv[3Srb36gRZN{[Xl? NXjhZnZtOOLCk{SwJI5O NWLWRno1PDhiaB?= NYPyOWZRcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MXqyOFA6QDd7OR?=
SK-N-BE NVjZflNyTnWwY4Tpc44hSXO|YYm= NYfKelNbOOLCk{SwJI5O NWL5WoQ1PDhiaB?= M3voeolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> NGXORVgzPDB7OEe5PS=>
HCC-LM3 NXnoXmMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPJNU0yODByIH7N MUeyOE81QC95MjDo MkP2SG1UVw>? MnXHbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXXWclhqOjRyOUO5OVY>
HepG2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13EW|EuOTByMDDuUS=> MoLCNlQwPDhxN{KgbC=> MkLISG1UVw>? M4TkeYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUOyOFA6Ozl3Nh?=
SMMC-7721 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zCWlEuOTByMDDuUS=> MV:yOE81QC95MjDo M2S3TGROW09? NFTVc5pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2HoPFI1ODl|OUW2
HCC-LM3 NXP0RlFZSXCxcITvd4l{KEG|c3H5 MXG1NEBvVQ>? NHzjcIc1QCCq NUD2W|R[TE2VTx?= M1nqbolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 MYCyOFA6Ozl3Nh?=
HepG2 NW\LO2RJSXCxcITvd4l{KEG|c3H5 NULvcWx5PTBibl2= MlLPOFghcA>? NUHidFRbTE2VTx?= NGTmXpNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? M{H0N|I1ODl|OUW2
SMMC-7721 MkDqRZBweHSxc3nzJGF{e2G7 NYW5[XVEPTBibl2= MlroOFghcA>? MYjEUXNQ NXHpdYxycW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? NI\vOHMzPDB7M{m1Oi=>
HCC-LM3 NH;xTZhHfW6ldHnvckBCe3OjeR?= NYrBTpp5PTBxMUCwJI5O NV;PdVlnOjRiaB?= NGXtN5VFVVOR NFW1VFll\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg NGHRe|QzPDB7M{m1Oi=>
HepG2 MojQSpVv[3Srb36gRZN{[Xl? M4PnclUxNzFyMDDuUS=> MUWyOEBp MXjEUXNQ NU\XSFM1\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> NH\kd4QzPDB7M{m1Oi=>
SMMC-7721 MWnGeY5kfGmxbjDBd5NigQ>? M2rkSVUxNzFyMDDuUS=> NXXOTJJ4OjRiaB?= MX3EUXNQ NHXjN3Jl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg M2jJdVI1ODl|OUW2
HCC-LM3 MoDXSpVv[3Srb36gRZN{[Xl? Mm\ZOVAwOTByIH7N M4KxS|I1KGh? MlTaSG1UVw>? NF31R|Nld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w NHTFWJYzPDB7M{m1Oi=>
HepG2 NFjNO5NHfW6ldHnvckBCe3OjeR?= MXO1NE8yODBibl2= NUTE[o54OjRiaB?= MnLqSG1UVw>? NYrJToN4\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= MWSyOFA6Ozl3Nh?=
SMMC-7721 NUjDfXV5TnWwY4Tpc44hSXO|YYm= NEnEdlU2OC9zMECgcm0> M37ycFI1KGh? MWXEUXNQ MY\kc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v MoLyNlQxQTN7NU[=
FaDu NVXrOmU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\hRVExOOLChX7N NX[xV4R2QC9zMD:xNkBp M4\GUoRqe3CuYYnl[EBiKHOrZ37p[olk[W62IHHu[EBxem:ub37n[YQhTzJxTTDhdpJme3RiYYSgPEBidmRiMUNihKVpKHCxc4SgdoVt\WG|ZR?= NFKx[GgzPDB{NkS4Ni=>
FaDu M3r0cmZ2dmO2aX;uJGF{e2G7 MlLCNVAx6oDHbl2= MWSyM|QwQC9zMjDo NHXrUlVqdmS3Y3XkJJAzOVejZkGvR4lxOcLiZYjwdoV{e2mxbh?= MV2yOFAzPjR6Mh?=
PC-3  NF;ZTJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HWdlAuOTBizszN NWricm5DOjRxNEivO|IhcA>? MlnHbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Ml7ENlM6QTF{MU[=
LNCaP Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXqVJkxNTVizszN NVHYZoZQOjRxNEivO|IhcA>? M4DGT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3raRlI{QTlzMkG2
RWPE-1  MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzSTXJmOC1{MDFOwG0> NYTmT2tCOjRxNEivO|IhcA>? MnP5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NH64OmkzOzl7MUKxOi=>
Capan-1 Mn\MSpVv[3Srb36gRZN{[Xl? NYe3S|QyOjVxNUCvNVAxKG6P NFTiPXo5NzJ2L{S4JIg> MnnZSG1UVw>? NUHYUGY5\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> NULoPXVxOjN7MkK4PFY>
L3.6pl NEfyW21HfW6ldHnvckBCe3OjeR?= MUiyOU82OC9zMECgcm0> MnTtPE8zPC92ODDo NVnnNnY4TE2VTx?= NYTvRXFX\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> MXuyN|kzOjh6Nh?=
CFPAC-1  M{\xZWZ2dmO2aX;uJGF{e2G7 MnXQNlUwPTBxMUCwJI5O NIflcIg5NzJ2L{S4JIg> NIHpWGlFVVOR MnTZ[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= NGrKflAzOzl{Mki4Oi=>
Capan-1 M1Ttd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HH[FI2NzVyL{GwNEBvVQ>? MkPTOFghcA>? MYjEUXNQ M3jQeZJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NU\CdFVjOjN7MkK4PFY>
L3.6pl MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj4NlUwPTBxMUCwJI5O NXPo[Gx1PDhiaB?= NITnbXhFVVOR MXzy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmrMNlM6OjJ6OE[=
CFPAC-1  NYDCc3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYeyOU82OC9zMECgcm0> MnnPOFghcA>? MXvEUXNQ NIjOZpBz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MV6yN|kzOjh6Nh?=
Capan-1 NVK3cpdmSXCxcITvd4l{KEG|c3H5 MnXhNlUwPTBxMUCwJI5O NXP2NI5FPDhiaB?= MUjEUXNQ NX7R[YdJcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXy4TVVtOjN7MkK4PFY>
L3.6pl NV3vZoNVSXCxcITvd4l{KEG|c3H5 NF;NemMzPS93MD:xNFAhdk1? NV[z[ZQyPDhiaB?= Moi1SG1UVw>? NWjEXJAzcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1vnV|I{QTJ{OEi2
CFPAC-1  MnTpRZBweHSxc3nzJGF{e2G7 NXLmSWl7OjVxNUCvNVAxKG6P NEjw[lQ1QCCq M{XtXWROW09? M4jubYlv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mn74NlM6OjJ6OE[=
HN22 NYHxR4VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jMbVAuOjBibl2= NVTPSVlNOjRxNEigbC=> NVfuTXBUTE2VTx?= M2DtNYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NXr1b5pROjN6N{eyN|U>
HSC4  NVHOT3AzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS0NE0zOCCwTR?= MmrJNlQwPDhiaB?= NX;QS3ROTE2VTx?= M{\TTIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NHjORZEzOzh5N{KzOS=>
HN22 NEHBZmtCeG:ydH;zbZMhSXO|YYm= MoDZNE0zOCCwTR?= MYC0PEBp MmXYSG1UVw>? MorybY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYj4PHU4OjN6N{eyN|U>
HSC4  NIH5cWNCeG:ydH;zbZMhSXO|YYm= NYDTRllTOC1{MDDuUS=> NF3ue5Q1QCCq NY\sSJZ5TE2VTx?= NIT0bHZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3vGU|I{QDd5MkO1
HN22 NWXufo5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGwMVIxKG6P M1PyblQ5KGh? NXzLPVhlTE2VTx?= MnLvbY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dNMg NFjiVYMzOzh5N{KzOS=>
HSC4  MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ywc|AuOjBibl2= MYm0PEBp NWrCUo1oTE2VTx?= M2n0Rolv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> NF3ofpYzOzh5N{KzOS=>
HN22 NFj6PW1HfW6ldHnvckBCe3OjeR?= Mo\zNE0zOCCwTR?= Mn7TOFghcA>? NXTme2hoTE2VTx?= Mlj3d5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg MnfxNlM5Pzd{M{W=
HSC4  NF;WNZRHfW6ldHnvckBCe3OjeR?= NWK2WW1JOC1{MDDuUS=> M{Pj[|Q5KGh? M{TJZWROW09? NXjTTlZVe3WycILld5NmeyCVcEGg[ZhxemW|c3nvcuKh MmLNNlM5Pzd{M{W=
Cal62 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7veINKSzVyPUOzJOKyKDRibl2= MWWyN|gzPDB4NB?=
Hth7 M2HWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[wN2lEPTB;MUWgxtEhOiCwTR?= NWfPNFJ5OjN6MkSwOlQ>
Hth83 NHPzS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3HTWM2OD1|NDFCtUA2KG6P Mlu5NlM5OjRyNkS=
C643 NI\te4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITkW2lKSzVyPUexJOKyKDFyIH7N MXSyN|gzPDB4NB?=
SW1736 M13sN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;WTWM2OD1|NTFCtUA5KG6P MWeyN|gzPDB4NB?=
T241 M3HUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTZ3INMxJFchdk1? NFLCNWozOzh{NEC2OC=>
T351 M1zWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;LTWM2OD13MDFCtUAyOCCwTR?= NFz4V2gzOzh{NEC2OC=>
BHP2-7 NF7tZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTN5INMxJFYhdk1? M3TRSVI{QDJ2ME[0
T238 NGXpXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPQdlVKSzVyPUGsOVAxKMLzIEKwNEBvVQ>? NV7zVoFsOjN6MkSwOlQ>
HCT8 NYHMSJNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULxTZhyPzJiaB?= MlLNSG1UVw>? NX;VeolkUUN3ME2xNk466oDLwsJihKkyNjlibl2= NFHpSYwzOzJ7OUO4PC=>
H630 M1zyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\VOlA4OiCq NYTCNXBCTE2VTx?= NW\j[FA2UUN3ME2xNk416oDLwsJihKk{NjFibl2= M2D0V|I{Ojl7M{i4
cH630 5-FU-res Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfjb5U4OiCq MlL6SG1UVw>? MkPDTWM2OD1zNT615qCKyrIkgJmxMlIhdk1? NEXUeFgzOzJ7OUO4PC=>
HCT116 M1TLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\yOGFwPzJiaB?= M2LVU2ROW09? MUjJR|UxRTFyLkhihKnDueLCiUKuNkBvVQ>? M{iyOFI{Ojl7M{i4
HCT116 p53−/− MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe3NkBp MnnxSG1UVw>? M2\Ic2lEPTB;OD625qCKyrIkgJmxMlchdk1? NEHrNWEzOzJ7OUO4PC=>
dHCT116 p21−/− MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLrWpZTPzJiaB?= NX3KSGNtTE2VTx?= NI\IdHNKSzVyPUWuPgKBkcLz4pEJNU4{KG6P NYHvSWFvOjN{OUmzPFg>
HT29 M1ewOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVm3NkBp NWXOcnp2TE2VTx?= MYTJR|UxRTF4LkRihKnDueLCiUKuN{BvVQ>? NYHXO2pGOjN{OUmzPFg>
LoVo NGfzeYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;kU2U4OiCq NEfZTJFFVVOR MYDJR|UxRTVwMfMAjeKy6oDLMD62JI5O NFvZcpAzOzJ7OUO4PC=>
RKO NEfFOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7UO|IhcA>? MUjEUXNQ MXHJR|UxRTdwOfMAjeKy6oDLMj6yJI5O NYjBWmduOjN{OUmzPFg>
SW480 MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXK3NkBp MnjGSG1UVw>? M2LDbmlEPTB;MUeuOgKBkcLz4pEJNE45KG6P MmTZNlMzQTl|OEi=
eSW620 NGXSVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT5O|IhcA>? NVfRNYVnTE2VTx?= MWLJR|UxRTlwMfMAjeKy6oDLMj6xJI5O MWmyN|I6QTN6OB?=

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02802163 Not yet recruiting Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen April 30, 2017 Phase 1|Phase 2
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT02890069 Recruiting Colorectal Cancer|Non-small Cell Lung Carcinoma (Adenocarcinoma)|Triple Negative Breast Cancer Novartis Pharmaceuticals|Novartis October 26, 2016 Phase 1
NCT01802879 Active, not recruiting Hematologic Neoplasms Novartis Pharmaceuticals|Novartis June 24, 2013 Phase 2
NCT00532675 Active, not recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 22, 2008 Phase 1
NCT02961816 Not yet recruiting Lymphoma M.D. Anderson Cancer Center February 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID